Case Study: A leading Fortune 500 biopharmaceutical company boosts cell culture runs by 70% with Catalyx’s OpenBIO bioreactor controls

Leading Fortune 500 Biopharmaceutical Company - Customer Case Study

A leading Fortune 500 biopharmaceutical company faced the challenge of modernizing its outdated bioreactor infrastructure across 140 units. They needed to implement modern Process Analytical Technology without interrupting ongoing operations, all while overcoming the inefficiencies of manual processes, limited scalability, and inconsistent capabilities from using multiple vendor systems. Catalyx was engaged to address these challenges with its OpenBIO Open Architecture Bioreactor Controller platform.

Catalyx implemented a scalable, vendor-neutral control platform in a phased rollout that caused minimal operational disruption. The solution standardized control across all bioreactors, which resulted in a 70% increase in cell culture runs, the reclamation of 30% more lab and production space, and an estimated annual ROI of over $300,000 per installation. Catalyx successfully provided the company with a unified system that enhanced data integration, centralized monitoring, and operational throughput.